key: cord-1053502-zoktdrfu
authors: Bitaraf, Ehsan; Ahmadi, Seyyed Amir Yasin; Gandomi-Mohammadabadi, Alireza; Noorani Mejareh, Zahra; Abdollahi, Bahare; Balasi, Javad; Moodi, Farzan; Hemmati, Nima; Kabir, Ali
title: Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study
date: 2021-07-02
journal: J Immunol Res
DOI: 10.1155/2021/9934134
sha: 13fb73728a1fba6009d415838a5fd03a21ad0eec
doc_id: 1053502
cord_uid: zoktdrfu

BACKGROUND: Regulation of the immune system is critical for fighting against viral infections. Both suppression and hyperactivity of the immune system result in failure of treatment. The present study was designed to show the effects of immune system-related medications on mortality and length of stay (LOS) in a cohort of Iranian patients with coronavirus disease 2019 (COVID-19). METHODS: A data mining study was performed on 6417 cases of COVID-19 covered by 17 educational hospitals of Iran University of Medical Sciences, Tehran. Association of a researcher-designed drug list with death and LOS was studied. For death outcome, logistic regression was used reporting odds ratio (OR) with 95% confidence interval (CI). For LOS, right censored Poisson regression was used reporting incidence rate ratio (IRR) with 95% CI. RESULTS: Among the corticosteroids, prednisolone was a risk factor on death (OR = 1.41, 95%CI = 1.03 − 1.94). This association was increased after adjustment of age interactions (OR = 3.45, 95%CI = 1.01 − 11.81) and was removed after adjustment of ICU admission interactions (OR = 2.64, 95%CI = 0.70 − 9.92). Hydroxychloroquine showed a protecting effect on death (OR = 0.735, 95%CI = 0.627 − 0.862); however, this association was removed after adjustment of age interactions (OR = 0.76, 95%CI = 0.41 − 1.40). Among the antivirals, oseltamivir showed a protecting effect on death (OR = 0.628, 95%CI = 0.451 − 0.873); however, this association was removed after adjustment of age interactions (OR = 0.45, 95%CI = 0.11 − 1.82). For reduction of LOS, the only significant association was for hydroxychloroquine (IRR = 0.85, 95%CI = 0.79 − 0.92). CONCLUSION: The results of such data mining studies can be used in clinics until completing the evidence. Hydroxychloroquine may reduce mortality in some specific groups; however, its association may be confounded by some latent variables and unknown interactions. Administration of corticosteroids should be based on the conditions of each case.

Coronavirus disease 2019 which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first found in Wuhan, China, In December 2019. According to a report, about 87.9% of hospitalized patients had fever and severe pneumonia occurred in 15.7% of patients [1] .

Clinically, there are two phases of the immunologic responses induced by SARS-CoV-2 infection: antiviral response and inflammation response. Potent immune response could eliminate the virus and prevent disease progression to severe stages in incubation period and at nonsevere stages. Therefore, at nonsevere stage, it is important to enhance immune responses. It seems that in immunocompromised patient, virus spread rapidly and leads to massive destruction in the affected organs [2] . Thus, the main cause of the delayed critical cascade of uncontrolled immune events may be the suppressed antiviral innate immune response induced by the virus and activation of the proinflammatory cytokines which lead to fulminant systemic inflammation [3] . The damaged cells induce innate inflammation by proinflammatory macrophages and granulocytes in the lungs. Lung inflammation is the main cause of respiratory disorders which is life-threatening at the severe stage [4] .

When COVID-19 progresses from severe to critical, patients may develop a severe cytokine storm and secondary acute respiratory distress syndrome, followed by shock, tissue perfusion disorders, and even multiorgan failure [1] . Although cytokine storm limits further spread of virus in the body, it induces secondary tissue damage through the secretion of large amounts of active mediators and inflammatory factors. It is one of main causes of death in COVID-19 patients; hence, it has been considered as a critical therapeutic target. Although the exact mechanism of cytokine storm is not understood yet, overactivation of the innate immune system and imbalanced angiotensin converting enzyme 2 (ACE2) expression seem to play a key role. Several clinical trials were conducted with the purpose of controlling cytokine storm. However, some questions need to be answered before widespread use of these treatments, i.e., what are the adverse effects of these therapeutic methods? When is the best time to start them? Are they the best possible treatment?

Regretfully, severe COVID-19 still has unclear pathophysiology and treatment. There are some uncertain immunomodulatory or immunosuppressive treatments for severe types of COVID 19 such as hydroxychloroquine, interleukin (IL)-6, and IL-1 antagonists [4] . There is currently no specific treatment drug to target SARS-CoV-2. So, deciding on potential treatment regimens for the prevention and treatment of severely ill COVID-19 patients remains a major challenge [5] . Briefly, the most important challenge is when to suppress and when to enhance the immune system through the current common drugs.

According to the above questions and limitations, we studied a cohort of Iranian patients to evaluate the effect of immune suppressants, modulators, and stimulants as well as some antivirals and antibiotics on mortality and length of stay (LOS) in patients with COVID-19.

A data mining project was conducted in the datacenter of Iran University of Medical Sciences, Tehran, Iran. The data was obtained from the 17 educational hospitals covered by the university between 20 March 2020 and 11 August 2020.

The inclusion criteria were being confirmed case of COVID-19 by the government with ICD-10 code U07.1 and being hospitalized. The exclusion criteria for inferential analysis were discharge from hospital by personal consent, escape from hospital, or transfer to another center.

Background variables: The governmental ID of the patients was used to merge the other variables as a uniform dataset. Age, gender, intensive care unit (ICU) admission, date of admission, and condition on discharge were other background variables. The categories of condition on discharge were complete remission, relative remission, death, escape from hospital, discharge by personal consent, and transfer to another center. Only the patients in the first three categories of condition on discharge were regarded for inferential statistical analysis.

The drugs of study: A researcher-designed drug list was prepared. The names of the variables were as the following. Sofosbuvir (indicating sofosbuvir/daclatasvir), lopinavir (indicating lopinavir/ritonavir), ribavirin, favipiravir, oseltamivir, interferon, metronidazole, linezolid, dexamethasone, hydrocortisone, budesonide (as nebulizer), prednisolone, methylprednisolone, infliximab, mycophenolate, IVIG (intravenous immunoglobulin), vitamin C, azathioprine, ciclosporin, tacrolimus, aspirin, warfarin, clopidogrel, acetaminophen, diphenhydramine, antivirals (indicating any kind of antiviral), CSF (colony stimulating factor), cephalosporins, macrolides, fluoroquinolones, lincosamides, glycopeptides, carbapenems, cotrimoxazole, glucocorticoids (any kind of glucocorticoid), heparin_group (indicating unfractionated heparin and enoxaparin), and hydroxychloroquine.

Outcome variables: The outcome variables were death and LOS. Death was a category of the variable condition on discharge, and LOS was the difference between admission date and discharge date.

Generated variables: Some new variables were designed and generated by the researchers. Death was generated as a binary variable from condition on discharge. Age group was generated from age. Underlying drugs was a binary variable indicating receiving of at least one of the drugs showing underlying infectious or cardiovascular disease of a patient or having diabetes (linezolid, warfarin, clopidogrel, fluoroquinolones, lincosamides, glycopeptides, carbapenems, cotrimoxazole, insulin, or oral antidiabetic agents).

Source. The source of the primary data was Iranian integrated care electronic health record (locally called SEPAS). SEPAS is a repository for storing health-related information for each individual. This repository has been created at the national level, in Iran.

Mining. This process was performed to study all the possible two by two associations between the variables. Correlation plot and dendrogram were used to show accompaniment of the variables (Figures 1 and 2 ). Support and confidence methods were also used. Support (variable ⟶ death) was defined as the probability of simultaneous positivity of the variable and death in all the samples. Confidence (variable ⟶ death) was defined as the probability of simultaneous positivity of the variable and death in all the patients with positivity of that variable.

Clustering. All the individual data was clustered as a heat map to classify the patients based on their variables ( Figure 3 ).

To study univariate associations of the binary variables with death, the chi square test was used, 2

Journal of Immunology Research and also relative risk (RR) and attributable risk (AR) were reported based on two by two cohort tables. To study univariate associations of the binary variables with LOS, the independent t-test was used. Bonferroni correction was applied on the P values. Regression modeling was used to adjust the effects the covariates. For death outcome, logistic regression was used reporting odds ratio (OR) with 95% confidence interval (CI). To study the performance of the model postestimation receiver operating characteristics (ROC) curve was used with reporting area under ROC curve (AUC). For LOS, right censored Poisson regression was used reporting incidence rate ratio (IRR) with 95% CI. Although we were supposed to use stepwise method to remove the nuisance making covariates, we used the enter method instead, because of some reasons: (1) our dataset was too complex to decide about a specific model of the con-sidered covariates, (2) some covariates were merely representative of some latent (unknown) variables, and we needed their adjusting effect rather than their own effects, and (3) since it was a preliminary report of this data mining study, we wanted to observe justice between all the covariates. Smith (2018) believed that the stepwise method might not be useful for big data [6] . Nevertheless, we designed a clinical modeling for hydroxychloroquine and another one for dexamethasone in which all the covariates were statistically significant. Dataset creation and data analysis were conducted in Stata 14 (StataCorp LLC, Texas, US) and R 3.6.3 (R foundation, Austria). 

A total of 6417 hospitalized confirmed cases were selected from 20 March 2020 to 11 August 2020 (Figure 4(a) ). Among them, 61.2% were completely recovered, 13.8% were partially recovered, 19.3% were died, 4.5% were discharged by personal consent, 0.9% were transferred to another center, and 0.2% escaped from the hospital. The mean age was 56:89 ± 20:95 years, and 56% of the patients were male. About 27.3% of the patients were admitted to ICU. The mean of LOS was 6:23 ± 6:46 days (with interquartile range 2 -8 days) (Figure 4(b) ). Finally, 6054 cases remained for analysis after removing the cases discharged by personal consent, transferred to another center, and who escaped from the hospital. According to the association rule mining, age, ICU admission, glycopeptides, and carbapenems were associated with death, and ICU admission, glycopeptides, and carbapenems were associated with increased LOS (correlation coefficient > 0:2, P < 0:001) ( Table 1 ). The most dominant and significant correlation was for the correlation of glycopeptides and carbapenems (Figures 1 and 2 ). All the cases were clustered according to their individual data. The most prevalent drugs were heparin_group, hydroxychloroquine and cephalosporins, respectively ( Figure 3 ). showed risk association, respectively, whereas cephalosporins (RR = 0:83) and macrolides (RR = 0:83) showed protecting association. No significant association was found for hydroxychloroquine (RR = 0:96) ( Table 2) .

Logistic regression was used to model the associations of the variables with death. Accordingly, age, male gender, ICU admission, prednisolone, lincosamides, glycopeptides, and 5 Journal of Immunology Research carbapenems were risk predictors, whereas oseltamivir, cephalosporins, macrolides, and hydroxychloroquine were protecting predictors. At the next step, age interactions were added to the model. Accordingly, lopinavir became a risk predictor, and the protecting association of oseltamivir, macrolides, and hydroxychloroquine did not remain. At the final step, the interactions of ICU admission with the significant variables of the previous step were added to the model. Accordingly, the risk association of prednisolone was removed. None of the risk associations were more dominant than the association of ICU admission (considering ICU admission as a calibrator for lack of being a clinical risk factor in spite of being a risk predictor with OR = 6:26). The only protecting predictor of death was cephalosporins (OR = 0:45, 95%CI = 0:24 − 0:85, P = 0:015) ( Table 3 ). The performance of the final step of this model for prediction of death is shown (AUC = 81:8%), and this model was more of specific rather than being sensitive ( Figure 5 ).

Marginal analysis was performed on the final step of the logistic regression model to show the interactions of the variables with ICU admission at each age. After age 60, mortality in males was higher in both ICU admitted and unadmitted patients ( Figure 6 ). Among the antivirals, lopinavir and oseltamivir were studied. Lopinavir was helpful in the ICU admitted patients after the age of 60. In patients without ICU admission, it might be harmful. Oseltamivir showed protecting effect in both ICU admitted and unadmitted patients ( Figure 7 ). Among the antibiotics, cephalosporins were protective up to age 60 especially in ICU admitted patients. Protecting effect of macrolides was not dominant ( Figure 8 ). Among the drugs of the immune system, hydroxychloroquine reduced mortality at most ages in both ICU admitted and unadmitted patients. Prednisolone was associated with increased mortality in ICU admitted patients. Hydrocortisone and dexamethasone showed no protecting or harmful effect. Methylprednisolone was helpful before the age of 60 in ICU admitted patients. Budesonide nebulizer seemed to be protecting but nonsignificant at many ages. IVIG was helpful by the age of 60 in ICU admitted patients. No significant association was found for vitamin C, but it might be helpful at ages more than 80 ( Figure 9 ).

According to the controversial findings of hydroxychloroquine, a model was designed including age, ICU admission, hydroxychloroquine, underlying drugs (drugs for underlying cardiovascular or severe infectious diseases or drugs of diabetes), and their significant interactions. Accordingly, hydroxychloroquine showed a protecting effect before (OR = 0:79, 95%CI = 0:69 − 0:92, P < 0:001) and after (OR = 0:79, 95%CI = 0:69 − 0:92, P < 0:001) adjusting the interactions; however, interaction of receiving underlying drugs with hydroxychloroquine was significantly harmful (OR = 1:46, 95%CI = 1:06 − 2:03, P = 0:022) ( Table 4 ).

According to the controversial findings of dexamethasone, a model was designed including age, ICU admission, underlying drugs, underlying drugs (drugs for underlying cardiovascular or severe infectious diseases or drugs of diabetes), and their significant interactions. Accordingly, dexamethasone showed a harmful effect (OR = 1:18, 95%CI = 1:02 − 1:37, P = 0:025) ( Table 5 ).

For this part, all the analyses were done on the improved cases. Univariate wise, associations of the variables with LOS were studied by the independent t-test. Most variables were associated with increased LOS. No variable was observed to decrease LOS significantly. Multivariable wise, right censored Poisson regression was used according to the distribution of LOS (Figure 4(b) ). Among the variables, age and hydroxychloroquine were associated with decreased LOS (P < 0:001). Among the risk associations, ciclosporin and infliximab were more dominant than the association of ICU admission Journal of Immunology Research Journal of Immunology Research (as a calibrator for lack of being a risk factor instead of being a risk predictor with IRR = 1:24) ( Table 6 ). Marginal analysis for interaction of the hydroxychloroquine and ICU admission at each age is shown. Accordingly, up to the age of 40 hydroxychloroquine was associated with decreased LOS and after the age of 40, it was associated with increased LOS in both ICU admitted and unadmitted patients ( Figure 10 ). 9 Journal of Immunology Research Table  3 : Logistic regression model for association of the variables with odds of death (in hospitalized improved or dead cases, the other cases were removed).

Step 1: adjusted with each other

Step 2: step 1 plus adjustment with age interactions 10 Journal of Immunology Research Table  3 : Continued.

Step 1: adjusted with each other

Step 

According to the aims of our study, three main groups of drugs were investigated including antibiotics, antivirals, and drugs of the immune system. Of course, from the viewpoint of pharmacology, antibiotics and antivirals are chemotherapeutic agents and affect the immune system. We used regression modeling to adjust the confounding effects of the drugs. It seems that age was the most important comorbidity factor [7] and therefore, we adjusted its effect and its interactions in our models. Our association rule mining showed a rationale between the pairs of the variables, for example, the correlation of aspirin and clopidogrel indicating the patients with coronary artery disease. Other associations can also be detected (Figures 1  and 2) . Individual data clustering showed that the most prevalent drug was the heparin_group-even more than hydroxychloroquine-due to our national protocol for anticoagulant therapy (Figure 3 ). For the associations of the dugs with the COVID-19 outcome, we discussed each drug sepa-rately. Before us, RECOVERY trial (randomized evaluation of COVID-19 therapy) had studied the effects of many of the drugs investigated in our study on thousands of participants.

In the cohort table, it was a risk factor for death. Regression wise, there was no association with death and LOS. It seems that its administration to complicated cases resulted in showing as risk factor in the cohort table. However, it seems that it does not have a beneficial effect. Unlike our study, an individual participant data meta-analysis showed that this drug could improve time to clinical recovery and reduce all causes of mortality. Many of the participants were Iranian [8] . Our association rule mining showed that its administration was usually along with dexamethasone indicating that our centers used it for more critical patients. It was not clear whether this combination was helpful for these patients or not.

In the cohort table, it was a risk factor. Regression wise, it was a risk factor for death after adjusting the interactions of age and ICU admission. However, its odds ratio was lower than ICU admission (2.84 vs 6.26) as the calibrator for the second generation null hypothesis (i.e., being clinically significant). Briefly, its effect was interaction-dependent. Marginal analysis showed a protecting effect for death in ICU admitted patients with age more than 60. It was a new finding in this study; however, its side effects and drug-drug interactions should be regarded for using in such patients [9] . Some meta-analyses did not show a beneficial effect [10, 11] . Our association rule mining showed that its administration was usually along with diphenhydramine and glucocorticoids mostly in ICU admitted patients with longer hospitalization. Predictive margins with 95% CIs Figure 6 : Association of gender with probability of death based on age and ICU admission (from logistic regression of Table 3 , step 3). [13] . Our association rule mining showed that its administration was usually along with Ribavarin. Maybe some patients had received this drug for influenza prophylaxis due to their underlying conditions. However, it was the most effective antiviral agent in our study.

4.1.6. Metronidazole. In the cohort table, it was a risk factor. Regression wise, there was no association with death and LOS. It seems that its administration to complicated cases resulted in showing as risk factor in the cohort table. Our association rule mining showed that its administration was high in patients with immunosuppressive drugs including ciclosporin, mycophenolate, and tacrolimus. We found no clinical study; however, some researchers considered a potential beneficial effect because of its anti-inflammatory effect and decreasing neutrophil count [14] .

In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, there was no association with death and LOS. There was not a related clinical study. Our association rule mining showed that its administration was high in the patients receiving IVIG.

In the cohort table, they were protecting factors. Regression wise, they were protecting factors for death while there was no effect on LOS. Marginal analysis showed that this protecting association was more dominant in younger ICU admitted patients. Our association rule mining showed that its administration was correlated with macrolides. It was not clear whether the protecting association of cephalosporins was due to its correlation with macrolide administration or due to its administration to more simple cases (the bias of selection by indication) or due to its own effect. In general, the associations of antibiotics with COVID-19 outcome are discussed with two aims: one of them is their effect on bacterial coinfections, and the second one is their antiviral effect. A computational analysis showed that chephalosporins had a potential binding ability to SARS-Cov-2 [15] . If an antibiotic shows a harmful effect, it may be representative of the effect of an underlying bacterial infection. Hence, if an antibiotic shows a protecting effect, this protecting effect is more reliable than that the harmful effect.

In other words, it shows that these antibiotics have beneficial effect in spite of the underlying bacterial disease of the patients.

4.1.9. Macrolides. In the cohort table, it was a protecting factor. Regression wise, there was no association with death and LOS. Of course, in step 1 of our logistic regression analysis, it showed a protective association. This possible protecting association was more dominant in older patients but similar response was observed in ICU admitted and unadmitted patients. Since macrolides increase QT Figure 7 : Association of lopinavir/ritonavir (a) and oseltamivir (b) with probability of death based on age and ICU admission (from logistic regression of Table 3 , step 3).

13 Journal of Immunology Research interval, its contraindications should be regarded. A metaanalysis showed that azithromycin increased mortality in combination with hydroxychloroquine [16] .

In the cohort table, it was a risk factor. Regression wise, it was a risk factor for LOS. Our association rule mining showed that its administration was correlated with administration of hydrocortisone. 4.1.11. Lincosamides. In the cohort table, it was a risk factor. Regression wise, there was no association with death and LOS.

4.1.12. Glycopeptides. In the cohort table, this group of anibiotics was a risk factor. Regression wise, it was a risk factor for death and LOS. Our association rule mining showed that its administration was usually along with carbapenems. Its odds ratio was not significantly lower than the odds ratio of ICU admission (5.38 vs 6.26) as the calibrator for the second generation null hypothesis (i.e., being clinically significant). It means that it can show severity of the underlying infectious comorbidity like ICU admission shows severity of the disease. Previous studies have shown that bacterial coinfection might occur in severe cases of COVID-19. This coinfection is not easy to follow because the inflammatory biomarkers are not specific for it [17, 18] . 4.1.13. Carbapenems. Their effect was approximately similar to glycopeptides as discussed above.

4.1.14. Cotrimoxazole. In the cohort table, it was not a risk factor. Regression wise, there was no association with death and LOS. Our association rule mining showed that its administration was correlated with azathioprine. 15 Journal of Immunology Research the cohort table might be due to its administration to more sever patients. Our association rule mining showed that its administration was correlated with acetaminophen.

4.1.16. Dexamethasone. In the cohort table, it was a risk factor. Regression wise, there was no association with death and LOS. In a meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids (dexamethasone), compared with usual care or placebo, was associated with lower 28-day all-cause mortality [19] . Nevertheless, its routine administration is not recommended according to our results (marginal analysis did not Table 3 , step 3). 16 Journal of Immunology Research 17 Journal of Immunology Research show a protecting effect). Our association rule mining showed that its administration was correlated with sofosbuvir. According to the controversies, we decided to design a practical model. Although based on this model, dexamethasone showed a harmful effect (Table 5) , its odds ratio was lower than the odds ratio of ICU admission. Based on the results of the RECOVERY collaborative group, only patients with mechanical ventilation benefit from dexamethasone [20] .

4.1.17. Hydrocortisone. In the cohort table, it was a risk factor for death. Regression wise, there was no association with death and LOS. Our association rule mining showed that its administration was correlated with fluoroquinolone. Marginal analysis did not show a protecting effect. 4.1.18. Budesonide. In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, there was no association with death and LOS. Our association rule mining showed that its administration was correlated with sofosbuvir and dexamethasone. Marginal analysis did not show a protecting affect.

In the cohort table, it was a risk factor for death. Regression wise, there was no association with LOS. According to our logistic regression, it was a risk factor for death, but this association was removed after adjusting the interactions of ICU admission. In a systematic review of 89 studies, administration of low-dose prednisolone had beneficial impacts on COVID-19 [21] . However, it seems that its administration without an indication other than COVID-19 may be harmful according to our results. Our association rule mining showed that its administration was correlated with death, glycopeptides, and carbapenems. It showed that its administration was common in patients with underlying infectious diseases.

4.1.20. Methylprednisolone. In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, it was associated with increased LOS after adjusting the interactions of age and ICU admission, but there was no association with death. Our association rule mining showed that its administration was correlated with ribavirin and oseltamivir. Although our results could not show a significant protecting effect on death, it seemed that methylprednisolone pulse might be useful in critically ill patients according to the literature [22, 23] . Marginal analysis showed that it was protective in ICU admitted patients with lower ages. 4.1.21. Infliximab. In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, it was associated with increased LOS after adjusting the interactions of age and ICU admission, but there was no association with death. Our association rule mining showed that it was in the cluster of immunosuppressive agents (Figure 2 , right cluster).

There was not enough observation to judge. Our association rule mining showed that its administration was correlated with tacrolimus.

In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, there was no association with death and LOS. A metaanalysis of two studies with total of 383 critical COVID-19 patients showed that administration of high-dose IVIG in first week of disease course especially in first 2 days was significantly associated with lower mortality and hospital stay rate [24] . Our association rule mining showed that it was in the cluster of immunosuppressive agents (Figure 2 , right cluster).

In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, there was no association with death but an increased in LOS was seen. Vitamin C has potentially antiviral effects through producing free radicals and rising antiviral cytokines; however, putting study design problems aside, not enough evidence for routine use of vitamin C in COVID-19 patients was found [25, 26] . Our association rule mining showed that its administration was usually along with favipiravir, interferon, and acetaminophen. Table 4 ). 18 Journal of Immunology Research than about 40. Nevertheless, literature did not support our results [27, 28] . In addition, the results of the RECOVERY collaborative group did not support a protecting effect for hydroxychloroquine [29] . According to the controversies, we decided to design a practical model. Using this drug in patients with diabetes or underlying cardiovascular or infectious diseases is not recommended. Its drug interactions about increasing QT interval should be regarded. However, its administration to other hospitalized patients may be helpful according to our results.

4.1.30. Aspirin. In the cohort table, it was a risk factor for death. Regression wise, there was no association with death but an increase in LOS was seen. Our association rule mining showed that its administration was correlated with clopidogrel showing cardiovascular disease in such patients.

4.1.31. Warfarin. In the cohort table, it did not show a significant association after bonferroni correction. Regression wise, there was no association with death and LOS . Our association rule mining showed that it was in the cluster of immunosuppressive agents (Figure 2 , right cluster).

4.1.32. Clopidogrel. Our association rule mining showed that its administration was correlated with aspirin showing cardiovascular disease in such patients.

In the cohort table, it was a risk factor for death. Regression wise, there was no association with death and LOS. In a systematic review of 11 studies, administration preventive doses of anticoagulants, including low-molecular weight heparins or unfractionated heparin were indicated to all hospitalized patients with COVID-19 and had beneficial impacts on them [30] . Although we did not find a beneficial effect, it may be necessary for prevention of pulmonary thromboembolism.

4.1.34. Acetaminophen. In the cohort table, it was a risk factor for death. Regression wise, there was no association with death but an increase in LOS was seen. Our association rule mining showed that its administration was correlated with interferon, vitamin C, and favipiravir.

4.1.35. Diphenhydramine. In the cohort table, it was a risk factor for death. Regression wise, there was no association with death but an increase in LOS was seen. Our association rule mining showed that its administration was correlated with lopinavir/ritonavir, glucocorticoids, LOS, and ICU.

It was a primary report of a complex dataset. Therefore, this article did not have an enough space for subgroup and more specific analyses. In addition, in a data mining study, the patients, the exposures, and the interventions are not based on the design of the researcher but all of them are based on the existed indications. In the case of ours, many drugs were not clinical trial administration but they were used for underlying indications of the patients. In other words, we had a bias called selection by indication (selection bias confounded by indication). This bias resulted that some simple drugs showed protecting association due to administration to simple cases, and some more specific drugs showed risk association due to administration to complex cases. Regression modeling could help us to overcome these limitations. Nevertheless, our models were complex with some nuisance making covariates. However, the stepwise method showed similar results (tables not shown). Being retrospective was another limitation in our study. Prospective studies and well-designed clinical trials should be performed regarding the effective covariates and interactions such as ICU admission and underlying diseases.

As a data mining study, it was not conclusive whether the protecting or risk associations were due to causation or they were confounded by bias in case selection for each drug. We could not reach a model for exact prediction of the outcome. Association of hydroxychloroquine with COVID-19 outcome was controversial. Although hydroxychloroquine showed a protecting effect in our regression modeling of all the drugs, this association did not remain after adjusting the interactions. It seems that the associations of hydroxychloroquine and other drugs are correlated with some known and unknown interactions. Administration corticosteroids should be based on the conditions of each case. Protective effects of cephalosporins was another notable finding. The data of this study was for the time when using remdesivir was not common and available in our country and also we had extra ICU mortality in the mentioned period of time.

As a preliminary report, the results of this study should be used for hypothesis creation for clinical trials or hypothesis creation for more specific data mining studies. The approach and methodology of this study is suggested to be used for other diseases and health issues.

The data cannot be taken out offline from the datacenter due to security and ethical reasons. SAYA and AK are available to perform further requested analyses (ahmadi.say@iums.ac.ir, kabir.a@iums.ac.ir).

There is no potential or real conflict of interest including financial, related to drug companies, and political.

As a team work in our data mining committee, all the authors participated in study design, data collection, and drafting the manuscript. Specifically, EB did programming in databases. SAYA wrote and performed commands in software packages, and AK performed critical revision. All the authors approved the final version of the manuscript. It is emphasized that Ehsan Bitaraf and Seyyed Amir Yasin Ahmadi are equal first authors.

19 Journal of Immunology Research

Rational use of tocilizumab in the treatment of novel coronavirus pneumonia

COVID-19 infection: the perspectives on immune responses

Dysregulation of the immune system as a driver of the critical course of the novel coronavirus disease 2019

Controlling cytokine storm is vital in COVID-19

An update on current therapeutic drugs treating COVID-19

Step away from stepwise

Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection

Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis

Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir

Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and metaanalysis

Safety and efficacy of lopinavir/ritonavir combination in COVID-19: a systematic review, meta-analysis, and meta-regression analysis

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Oseltamivir, lopinavir/ritonavir and reduning may improve survival of COVID-19 patients with high-risk

Metronidazole; a potential novel addition to the COVID-19 treatment regimen

A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and metaanalysis

Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis

Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or "just" a marker of bacterial coinfection?

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Dexamethasone in hospitalized patients with Covid-19

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Successful use of methylprednisolone for treating severe COVID-19

Evaluation of current medical approaches for COVID-19: a systematic review and metaanalysis

The role of vitamin C, vitamin D, and selenium in immune system against COVID-19

Vitamin C for the treatment of COVID-19: A living systematic review

Hydroxychloroquine in patients with COVID-19: a systematic review and meta-analysis

No benefit of hydroxychloroquine in COVID-19: results of systematic 20 Journal of Immunology Research review and meta-analysis of randomized controlled trials

Effect of hydroxychloroquine in hospitalized patients with Covid-19

COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention